Connect with us

Tech

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Published

on

Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago.

The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.

While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.

>

Continue Reading

Tech

Anthropic says its biology lab has already found something big

Published

on

Last week, Anthropic confirmed that it was operating a wet biology lab in the Bay Area where it uses its AI models to run physical experiments. This week, the AI giant announced that this lab has already made what it believes is a big discovery: a new enzyme “system” that has certain “properties reminiscent of CRISPR,” as Anthropic describes it.

CRISPR is a natural immune system used by bacteria to fight off viruses that has become a gene-editing technology widely used by researchers.

Essentially, what Anthropic says it found is a previously unknown enzyme system hidden in the DNA of bacteriophages, which are viruses that infect and replicate within bacteria. Anthropic’s researchers say this system behaves similarly to CRISPR in that it can “perform operations like cutting, copying, and pasting DNA.”

It will be up to the broader research community to validate how big, or new, this discovery actually is. Anthropic CEO Dario Amodei acknowledges that the discovery was based on the previous work of others and that a team from Stanford previously discovered a system “that is in some ways similar to the one Claude found,” he wrote on X.

But Amodei and Anthropic are not just emphasizing the discovery. They are touting it was found “mostly, though not entirely, by Claude,” the CEO wrote.

On the one hand, that is astounding. This lab was only established this spring, (though Anthropic declined to be more specific about how many months it has been open). A discovery in just a few short months would be speedy enough work, but the team said it actually only took Claude 21 hours of concerted effort. Claude searched through data using about 950 agents that burned through 210 million tokens.

Still, the revelation that Anthropic has been conducting biology experiments comes right after AI CEOs, including Amodei, publicly admitted that models have become so capable, and so potentially dangerous, that the industry must slow down and develop safety-testing procedures. This after a couple of his employees publicly said earlier this month that there’s a risk AI could kill us all.

Amodei himself has said one of the things he fears most its that AI could be used for bioterrorism. But he also believes AI will “cure most diseases in 5-10 years,” he wrote. So Anthropic has clearly decided the rewards are worth the risks.

Given that, perhaps the biggest reveal in this news isn’t the discovery itself, but that the biology lab hasn’t let Claude loose. The physical experiments were done by humans.

“Our lab, located in the Bay Area, looks like a typical molecular biology lab. We do research that involves only the lower-levels of the biosafety risk level (BSL-1 and BSL-2) and we do not handle pathogens that can infect humans. All of the lab work is performed by human scientists.”

It’s also true that AI-powered biological research is hardly unique to Anthropic. Researchers from Stanford just published a paper on the work they are doing with LLMs and CRISPR. Researchers at UC San Francisco used AI to design enzymes from scratch. Google launched its first AI-powered biology research tool, AlphaFold, back in 2020. So AI has clearly arrived in biological research beyond the AI labs pursuing it themselves.

Yet, Amodei hasn’t ruled out a fully automated biology lab in the future. “Eventually it may even be possible for Claude itself to safely perform the experiments by autonomously controlling lab equipment, with appropriate safeguards in place, but we aren’t doing that today,” he said.

.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

>

Continue Reading

Tech

Best Whoop Alternatives in 2026: Oura, Garmin, Fitbit, and More

Published

on

Compare the best Whoop alternatives in 2026, including Garmin, Oura, Fitbit, Amazfit, and Polar for sleep, recovery, fitness, and value.

The post Best Whoop Alternatives in 2026: Oura, Garmin, Fitbit, and More appeared first on TechRepublic.

>

Continue Reading

Tech

iPhone 18 Pro Cheat Sheet: Price, Specs, Features and More

Published

on

The iPhone 18 Pro starts at $1,199 with the A20 Pro chip, variable-aperture camera, Siri AI, faster charging, and up to 2TB of storage.

The post iPhone 18 Pro Cheat Sheet: Price, Specs, Features and More appeared first on TechRepublic.

>

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.